Cutaneous T- cell Lymphoma Treatment Market Size, Share and Global Trend By Treatment (Topical therapy, Chemotherapy, Others), By End User (Hospitals, Clinics, Ambulatory surgery centers Others), and Regional Forecast, 2024-2032

In the fiscal year of 2018, Kyowa Kirin, Inc. received US FDA approval for Poteligeo (mogamulizumab-kpkc) injection indicated for the treatment of adult individuals suffering from Sezary Syndrome (SS) after minimum one prior systemic therapy. Cutaneous T-cell lymphomas (CTCLs) is a disorders described by abnormal development of malignant T-cells in the skin, causing tumors, plaques, and rashes. The high number of therapies in clinical trials and in the pipeline for the treatment of cutaneous T-cell lymphomas is anticipated to fuel the cutaneous T-cell lymphomas treatment market during the forecast period.

Increasing prevalence of cutaneous T-cell lymphomas and rise investment of research and development towards the diagnosis and detection of cutaneous T-cell lymphomas are expected to help in the growth of the global cutaneous T-cell lymphomas treatment market during the forecast period. The rise in demand for the chemotherapy and radiation therapy also expected to help in the growth of the global cutaneous T-cell lymphomas treatment market.

The high of cost treatment, lack of detection techniques and lack in awareness about the symptoms and treatment of cutaneous T-cell lymphomas in emerging countries are some of the factors restraining the growth of the cutaneous T-cell lymphomas treatment market.

Key Players Covered

Some of the major companies that are present in the global cutaneous T-cell lymphomas treatment market are Bristol-Myers Squibb Company, Kyowa Kirin, Inc. Actelion Pharmaceuticals Ltd., Helsinn Healthcare SA., Seattle Genetics, Inc., Mallinckrodt, Eisai Co., Ltd., and others.

SEGMENTATION

Among the treatment segmentation, topical therapy is anticipated to account for a large share in the global cutaneous T-cell lymphomas treatment market owing to the recent approvals and larger adoption of topical drugs for the treatment of cutaneous T-cell lymphoma.

Key Insights

• Pipeline analysis
• Reimbursement scenario in key countries
• Regulatory scenario for key countries
• Key mergers and acquisitions

Regional Analysis

The global cutaneous T-cell lymphomas treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is anticipated to hold the largest share in the global cutaneous T-cell lymphomas market in 2018 owing to the increasing prevalence of mycosis fungoides and a well-developed healthcare infrastructure leading to increasing demand for new and advanced cutaneous T-cell lymphomas treatment in the region. According to the Cutaneous Lymphomas Foundation, an estimated 30,000 people in the United States and 3,000 people in Canada are living with cutaneous lymphoma each year. Approximately 1,500–2,000 new cases are diagnosed each year across North America. The emerging countries of the Asia Pacific are expected to register comparative higher CAGR from 2019-2026 due to growing emphasis by healthcare organizations and governments for the development of detection and diagnostics techniques combined with increasing awareness of skin cancer among the patient pool.

Key Industry Developments

• In January 2019, Innate Pharma SA received Fast Track designation (FTD) from the U.S FDA for the drug IPH4102 indicated for the treatment of relapsed or refractory Sézary syndrome (SS).
• In January 2019, Bristol-Myers Squibb Company and Celgene Corporation announced the companies have entered into a merger agreement.
• In March 2017, Actelion Pharmaceuticals Ltd. received marketing approval from the European Commission for the product Ledaga (chlormethine gel) indicated for the treatment of mycosis fungoides-type cutaneous T-cell lymphoma.
• In November 2017, the U.S FDA approved the use of ADCETRIS (brentuximab vedotin) manufactured by Seattle Genetics, Inc. for the treatment of CD30-Expressing Mycosis Fungoides (MF).